Piramal Pharma Announces $80 Mn Expansion for Kentucky Facility

The $80 million investment will enhance the site’s production capabilities to meet the growing market demand for sterile injectables, including those used in ADCs.

Mumbai-based Piramal Pharma Solutions (PPS), a global Contract Development and Manufacturing Organization (CDMO) has announced the expansion of its sterile injectables facility in Lexington, Kentucky for a whopping sum of $80 million.

The $80 million investment will enhance the site’s production capabilities to meet the growing market demand for sterile injectables, including those used in antibody-drug conjugates (ADCs).

PPS, a part of Piramal Pharma, plans to expand the Lexington facility by 24,000 sq ft. The site currently handles sterile compounding, liquid filling, and lyophilization processes essential for sterile injectables. 

This expansion, expected to be completed by Q1 2027, aims to significantly increase the facility’s production capacity from 104 product batches annually to over 240 batches.

Furthermore, the expansion will support this program by adding a new filling line, two commercial-scale lyophilizers, a specialized capping machine, and an external vial washer. 

This equipment will allow the facility to handle larger batch sizes and more complex drug formulations.

"With the sterile injectables market continuing to grow, expanding our Kentucky facility is critical to maintaining our position as a reliable partner in this space. This investment allows us to support the increasing needs of our clients while reinforcing our commitment to delivering high-quality injectable products," said Peter DeYoung, CEO of Piramal Pharma Solutions. 

In addition to bolstering manufacturing capacity, the expansion will create over 40 full-time jobs, contributing to the local economy. The new roles will support the advanced manufacturing processes introduced at the site, enhancing operational efficiency and capacity.

DeYoung highlighted the local impact, noting, "This expansion not only strengthens our capabilities but also contributes to the economic development of the Lexington area. We are proud to create new job opportunities and invest in the local workforce, vital to our ongoing success."

The Lexington facility plays a crucial role in PPS’s strategy to support its clients in the pharmaceutical and biologics sectors. The expansion, funded through bank loans and internal resources, will allow PPS to scale production to meet the increasing demand for complex biological drugs.

PPS has positioned itself as a significant player in biologics, particularly in the ADC space, witnessing rapid growth as pharmaceutical companies seek specialized manufacturing solutions. The Lexington facility’s expansion comes as PPS focuses on enhancing its global footprint in sterile injectables manufacturing.

Stay tuned for more such updates on Digital Health News.